Volume 2 · Issue 5 (2025)
Advances in the Mechanism of PI3K Signaling Pathway in Glioblastoma
Wenhan Zhang
Carlucci American International School of Lisbon, Portugal
Abstract: Glioblastoma (GBM), classified as a WHO Group IV astrocytoma, is the most common highly malignant glioma in adults, accounting for 50% -55% of neuroectodermal-derived tumors. It is characterized by aggressive behavior, high recurrence rates, and extremely poor prognosis [1]. The phosphatidylinositol 3-kinase (PI3K) signaling pathway, functioning as a core regulatory network within cells, shows abnormal activation in 88% of GBM cases. This pathway plays a crucial role in tumor progression by regulating key biological processes including cell proliferation, metabolism, migration, and drug resistance [2]. Recent advancements in molecular biology have deepened our understanding of PI3K's mechanisms in GBM, particularly in subtype-specific functions, non-classical signaling pathways, and therapeutic target development. This systematic review examines the composition and activation modes of the PI3K signaling pathway, its core mechanisms in GBM, and recent progress in targeted therapies, aiming to provide theoretical foundations for precision treatment strategies in this challenging disease.
Keywords: Glioblastoma; PI3K Signaling Pathway; Therapeutic Target
References
[1]
Zhang Xian: Criticism of Social Darwinism by Marx and Engels and Its Contemporary Value, Research on Socialist Core Values, 2024, No.10, p. 80.
[2]
Chen Qianxue. Advances in the Diagnosis and Treatment of Glioblastoma. Journal of Cancer Prevention and Treatment, 2022,49(11):1103-1106.
[3]
Akinleye A, Avvaru P, Furqan M, et al. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. Journal of hematology & oncology, 2013, 6(1): 88.
[4]
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G et al: The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021, 23(8):1231-1251.
[5]
Fu Jingyu, Zhang Yuxi, Yang Fan, Peng Daiyun, Liu Jiangyan. 18F-FDG PET combined with MRI visual analysis demonstrates high diagnostic efficacy for atypical primary central nervous system lymphoma and high-grade glioma. Journal of Molecular Imaging, 2025,48(07):800-806.
[6]
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-996.
[7]
Scheurer ME, El-Zein R, Thompson PA, Aldape KD, Levin VA, Gilbert MR, Weinberg JS, Bondy ML: Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. Cancer Epidemiol Biomarkers Prev 2008, 17(5):1277-1281.
[8]
Niu Wanxiang, Mu Maolin, Zhang Hongwei, Ji Ying, Cheng Chuandong. Analysis of Secondary Primary Malignant Tumors in Patients with Brain Gliomas. Journal of Stereotactic and Functional Neurosurgery, 2024,37(04):199-204.
[9]
Grueso E, Sánchez-Martínez C, Calvo-López T, et al. Antiangiogenic vascular endothelial growth factor-blocking peptides displayed on the capsid of an infectious oncolytic parvovirus: assembly and immune interactions. Journal of Virology, 2019, 93(19): 10.1128/jvi. 00798-19.
[10]
Khasraw M, Ameratunga M, Grommes C: Bevacizumab for the treatment of high-grade glioma: an update after Phase Ill trials. Expert Opin Biol Th 2014, 14(5):729-740.
[11]
Filley AC, Henriquez M, Dey M: Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget 2017, 8(53):91779-91794.
[12]
Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS et al: Phase III Randomized Trial Comparing the Efficacy of Cediranib as Monotherapy, and in Combination with Lomustine, Versus Lomustine Alone in Patients with Recurrent Glioblastoma. J Clin Oncol 2013, 31(26):3212-3218.
[13]
Lombardi G, De Salvo GL, Brandes AA, Eoli M, Rudà R, Faedi M, Lolli I, Pace A, Daniele B, Pasqualetti F et al: Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 2019, 20(1):110-119.
[14]
Alexander BM, Ba SJ, Berger MS, Berry DA, Cavenee WK, Chang SM, Cloughesy TF, Jiang T, Khasraw M, Li WB et al: Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. Clin Cancer Res 2018, 24(4):737-743.
[15]
Subramaniam B, Roy D, Woldegerima A, Subramaniam B, Roy D, Woldegerima A, et al. Dual treatment with Val-083 and AZD1775 shows potent anti-tumor activity in diffuse midline glioma models. npj Precision Oncology, 2025, 9(1): 209.
[16]
Wick W, Gorlia T, Bady P, Platten M, van den Bent MJ, Taphoorn MJB, Steuve J, Brandes AA, Hamou MF, Wick A et al: Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without Promoter Hypermethylation (EORTC 26082). Clin Cancer Res 2016, 22(19):4797-4806.
[17]
Pallet N, Legendre C. Adverse events associated with mTOR inhibitors. Expert opinion on drug safety, 2013, 12(2): 177-186.
[18]
Whittaker S, Madani D, Joshi S, Whittaker S, Madani D, Joshi S, et al. Combination of palbociclib and radiotherapy for glioblastoma. Cell death discovery, 2017, 3(1): 1-6.
[19]
Rahman R, Trippa L, Lee E Q, Rahman R, Trippa L, Lee E Q, et al. Inaugural results of the individualized screening trial of innovative glioblastoma therapy: a phase II platform trial for newly diagnosed glioblastoma using Bayesian adaptive randomization. Journal of Clinical Oncology, 2023, 41(36): 5524-5535.
[20]
Amzel L M, Huang C H, Mandelker D, Amzel L M, Huang C H, Mandelker D, et al. Structural comparisons of class I phosphoinositide 3-kinases. Nature Reviews Cancer, 2008, 8(9): 665-669.
[21]
Panwar V, Singh A, Bhatt M, et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal transduction and targeted therapy, 2023, 8(1): 375.
[22]
Ersahin T, Tuncbag N, Cetin-Atalay R. The PI3K/AKT/mTOR interactive pathway. Molecular BioSystems, 2015, 11(7): 1946-1954.
[23]
Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta. 2010; 1804: 433–439.
[24]
Carnero A, Blanco-Aparicio C, Renner O, Carnero A, Blanco-Aparicio C, Renner O, et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Current cancer drug targets, 2008, 8(3): 187-198.
[25]
De Jesus A, Keyhani-Nejad F, Pusec C M, De Jesus A, Keyhani-Nejad F, Pusec C M, et al. Hexokinase 1 cellular localization regulates the metabolic fate of glucose. Molecular cell, 2022, 82(7): 1261-1277. e9.
[26]
Li D, Ni S, Miao K S, Li D, Ni S, Miao K S, et al. PI3K/Akt and caspase pathways mediate oxidative stress-induced chondrocyte apoptosis. Cell Stress and Chaperones, 2019, 24(1): 195-202.
[27]
Xu J, Li Y, Kang M, Xu J, Li Y, Kang M, et al. Multiple forms of cell death: A focus on the PI3K/AKT pathway. Journal of Cellular Physiology, 2023, 238(9): 2026-2038.
[28]
Jin Zhaohui, Liu Liang, Qian Chunfa, et al. Metabolic Reprogramming Drives Radioresistance and Targeted Therapies in Glioblastoma. Chinese Journal of Radiation Oncology, 2025,34(8):839-846.
[29]
Tapial Martínez P, López Navajas P, Lietha D. FAK structure and regulation by membrane interactions and force in focal adhesions. Biomolecules, 2020, 10(2): 179.
[30]
Hu H H, Wang S Q, Shang H L, Hu H H, Wang S Q, Shang H L, et al. Roles and inhibitors of FAK in cancer: current advances and future directions. Frontiers in Pharmacology, 2024, 15: 1274209.
[31]
Misek S A, Chen J, Schroeder L, Misek S A, Chen J, Schroeder L, et al. EGFR signals through a DOCK180-MLK3 axis to drive glioblastoma cell invasion. Molecular Cancer Research, 2017, 15(8): 1085-1095.
[32]
Huang J, Liu Y, Wang G, Huang J, Liu Y, Wang G, et al. The Expression Profiles and Clinical Significance of Mixed Lineage Kinases in Glioma. Mediators of Inflammation, 2024, 2024(1): 5521016.
[33]
Misek S A, Chen J, Schroeder L, Misek S A, Chen J, Schroeder L, et al. EGFR signals through a DOCK180-MLK3 axis to drive glioblastoma cell invasion. Molecular Cancer Research, 2017, 15(8): 1085-1095.
[34]
Zhang H, Zhang Y, Zhang C, Zhang H, Zhang Y, Zhang C, et al. Recent advances of cell-penetrating peptides and their application as vectors for delivery of peptide and protein-based cargo molecules. Pharmaceutics, 2023, 15(8): 2093.
[35]
Zhao H, Wu C, Zhou X, Zhao H, Wu C, Zhou X, et al. Synergism between the phosphatidylinositol 3-kinase p110β isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation. Cancer Cell International, 2021, 21(1): 24.
[36]
Yin Xiuwen, Hao Chunyan, He Wubin. Accelerating Skin Wound Healing by Promoting Epidermal Cell Proliferation and Migration: A Study on Rhubarb Polysaccharides. Natural Products Research and Development, 2025,37(6):1020-1028,1069.
[37]
Zhang Zuoxin. Research on the Mechanism by Which Long-Chain Non-Coding RNA HOXD-AS2 Promotes Resistance to Chemotherapy with Temozolomide in Glioblastoma. Army Medical University, 2023.
[38]
Varghese R T, Liang Y, Guan T, Varghese R T, Liang Y, Guan T, et al. Survival kinase genes present prognostic significance in glioblastoma. Oncotarget, 2016, 7(15):20140-20151.
[39]
Pridham K J, Le L, Guo S, Pridham K J, Le L, Guo S, et al. PIK3CB/p110β is a Selective Survival Factor for Glioblastoma. Neuro-oncology, 2017.
[40]
Phung T L , Du W , Xue Q ,Phung T L , Du W , Xue Q , et al. Akt1 and Akt3 Exert Opposing Roles in the Regulation of Vascular Tumor Growth. Cancer Research, 2015, 75(1):40-50.
[41]
Reddy D, Kumavath R, Tan T Z, Reddy D, Kumavath R, Tan T Z, et al. Peruvoside targets apoptosis and autophagy through MAPK Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways in human cancers. Life Sciences, 2019, 241:117147.
[42]
Chaussade C, Rewcastle G, Kendall J, Chaussade C, Rewcastle G, Kendall J, et al. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochemical Journal, 2007, 404(3):449-458.
[43]
Hutchings K, Beck P J, Pridham K J, Hutchings K, Beck P J, Pridham K J, et al. Overcoming temozolomide resistance in glioblastoma through selective inhibition of phosphoinositide 3-kinase catalytic subunit. Journal of Clinical Oncology, 2023.
[44]
Ostrodka L, Samuel M, Sinclair T, et al.PI3 Kinase p110 Delta Is Required for Leukemic Cell Survival and Self-Renewal in t (8;21) Acute Myeloid Leukemia. Blood, 2016, 128(22):1553-1553.
[45]
Young R G, Ahmed N N, Reginato M J. New job for an old tool: PI3Kβ phosphorylates OGT to regulate acetyl-CoA in glioblastoma. Trends in Cell Biology, 2025, 35(5):361-363.
Download PDF